Zidimont Tablet contains Levocetirizine 5mg and Montelukast 10mg, a combination formulation used primarily for the management of allergic conditions such as allergic rhinitis and chronic urticaria. Levocetirizine is a third-generation non-sedative antihistamine that selectively inhibits peripheral H1 receptors, thereby reducing symptoms like sneezing, nasal congestion, rhinorrhea, and pruritus. Montelukast is a leukotriene receptor antagonist that blocks the action of leukotrienes, inflammatory mediators involved in bronchoconstriction, mucus secretion, and airway edema, making it effective in preventing asthma exacerbations and relieving allergic symptoms. The synergistic action of these two agents provides comprehensive relief from allergic manifestations by targeting different pathways in the allergic response. Zidimont is indicated for patients with seasonal or perennial allergic rhinitis and asthma, particularly when monotherapy is insufficient. It is generally well tolerated, with common adverse effects including headache, fatigue, and gastrointestinal disturbances. Caution is advised in patients with hepatic or renal impairment, and it should be used under medical supervision. Zidimont Tablet offers an effective therapeutic option for patients requiring combined antihistaminic and leukotriene receptor antagonist treatment to improve quality of life and symptom control in allergic disorders.